Polaryx Therapeutics
@polaryx.com
Clinical-stage biotech developing patient-friendly drug candidates for the treatment of lysosomal storage disorders. Nasdaq: $PLYX
Polaryx Therapeutics's Company Logos
Polaryx Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#2E80A8
Astral
46, 128, 168
200, 57, 42
73, 24, 0, 34
#D4C6B6
Soft Amber
212, 198, 182
32, 26, 77
0, 7, 14, 17
#945431
Mule Fawn
148, 84, 49
21, 50, 39
0, 43, 67, 42
About Polaryx Therapeutics
Polaryx Therapeutics is a biotech company focused on developing patient-friendly medicines for lysosomal storage disorders. Their innovative approach aims to provide precision medicines that address rare and intractable genetic diseases, such as pediatric genetic epilepsies. Led by a talented management team, including CEO and Chair of the Board Alex Yang, and CSO Hahn-Jun Lee, Polaryx Therapeutics has a wealth of expertise in fund formation, cross-border transactions, and investment experiences in multiple industry sectors.
They also have a strong focus on regulatory affairs, with a Head of Regulatory Affairs, Mary Shatzoff, who has over 25 years of experience in the pharmaceutical industry. With their dedication to developing breakthrough treatments and their commitment to improving the lives of patients, Polaryx Therapeutics is at the forefront of advancing the field of precision medicine
Company type
Privately Held
Year founded
2014
Company size
2-10 employees
